Brian K. Petroff, D.V.M., Ph.D.

Associate Professor
Dept. of Hematology/Oncology
Member, Center for Reproductive Sciences

Ph.D., The Ohio State University, 1996
D.V.M., The Ohio State University, 1998
Postdoctoral, University of Kansas Medical Center, 1999-2001

Our research efforts have a dual focus 1) prevention of ovarian aging and chemotherapy and other ovarian toxicant induced infertility 2) prevention of breast and ovarian cancers through the characterization and antagonism of promising targets in human and animal chemoprevention trials. Early work showing ovarian follicular loss in polluted environments (i.e. dioxin) mediated by the aryl hydrocarbon receptor was the underpinning for later work indicating that tamoxifen may protect against follicular loss from alkylating agent chemotherapy.  I was recruited to the Department of Medicine, Division of Hematology/Oncology in 2004 to collaborate on translational aspects of early prevention trials in breast and ovarian cancer. This included development of the first model of nearly simultaneous ER+ breast and ovarian pre-cancer which would be invaluable in assessment of risk and mechanism of action biomarker modulation for Phase II human prevention trials. In this manner investigators would be able to preview the effects of an intervention on the ovary as well as breast in a model which is hormonally analogous to a late premenopausal woman. During the validation of this model with the Selective Estrogen Receptor Modulator (SERM), tamoxifen, it was noted that tamoxifen could protect against carcinogen (DMBA) induced ovarian follicle loss and hence aid in preserving fertility. The observations were repeated for cyclophosphamide. The breast and ovarian cancer model itself is being used in a multi-PI multi-project Komen Promise Grant awarded in 2010. I have been instrumental in overseeing the development of more advanced molecular techniques to characterize biomarker change in breast chemoprevention trials from the small amounts of material available from random peri-aerolar fine needle aspirations including proteomics and stem cell markers, lipidomics, hormone measurements and gene expression after and laser capture micro-dissection. I have held a leadership position in the developing University of Kansas Cancer Center as coleader of Cancer Prevention since 2008.

Selected Publications

Hutt KJ, Shi Z, Petroff BK, Albertini DF. The environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin disturbs the establishment and maintenance of cell polarity in preimplantation rat embryos. Biol Reprod. 2010 May;82(5):914-20.

Jablonska O, Shi Z, Valdez KE, Ting AY, Petroff BK. Temporal and anatomical sensitivities to the aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin leading to premature acyclicity with age in rats. Int J Androl. 2010 Apr;33(2):405-12.

Kim SS, Lee JR, Jee BC, Suh CS, Kim SH, Ting A, Petroff BK. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010 Dec;53(4):740-52.

Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell KD, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh HW, Johnson KA. Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside. Cancer Prev Res. 2010. Oct;3(10):1342-50.

Ting AY, Petroff BK. Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. J Assist Reprod Genet. 2010. Nov;27(11):591-7.

Nynca A, Jablonska O, Slomczynska M, Petroff BK, Ciereszko RE. Effects of phytoestrogen daidzein and estradiol on steroidogenesis and expression of estrogen receptors in porcine luteinized granulosa cells from large follicles. J  Physiol Pharmacol. 2009 Jun;60(2):95-105.

Valdez KE, Shi Z, Ting A, Petroff BK. Effect of chronic exposure to the aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin in female rats on ovarian gene expression. Reprod Toxicol. 2009 28:32-37.

Ting AY, Kimler BF, Fabian CJ, Petroff BK. Tamoxifen prevents premalignant changes of  breast, but not ovarian, cancer in rats at high risk for both diseases. Cancer Prev Res (Phila). 2008 Dec;1(7):546-53.

Hutt K, Shi Z, Albertini, DF, Petroff BK. The environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin disrupts morphogenesis of the rat embryo. BMC Dev Biol. 2008 8:1-10

Shi ZQ, Valdez KE, Ting A, Gum S, Franczak A, Petroff BK. Chronic AhR ligand exposure accelerates reproductive aging via ovarian endocrine disruption at environmentally relevant exposures. Biol Reprod. 2007 76:198-202. 

Last modified: Feb 24, 2014

Brian K. Petroff D.V.M., Ph.D.


Brian K. Petroff, D.V.M., Ph.D.
Associate Professor
Dept. of Hematology/Oncology